Catalent has cut 96 jobs this week in what state records and industry outlets describe as the company’s third round of layoffs, hitting Baltimore-area facilities. The latest reductions, split between city and county locations, tighten the screws on Maryland’s gene-therapy and contract manufacturing hub and follow multiple rounds of cuts that began last summer.
According to the Baltimore Business Journal, the company eliminated 96 positions across two Baltimore sites in the newest round, after earlier trims at Catalent’s Harmans campus and at the University of Maryland BioPark. Catalent, which has its global corporate headquarters in Tampa and operates several Maryland facilities, has said via information on its corporate site that it is adjusting regional operations as customer demand shifts. The Business Journal reported that the company notified state officials about the cuts.
Earlier Rounds And State Records
State WARN filings and trade coverage show this latest move is part of a longer series of workforce reductions. An August 2025 notice disclosed around 350 affected employees across Harmans and Baltimore, followed by a November 2025 filing that trimmed additional roles. The Maryland Department of Labor’s public WARN log lists those earlier actions, and industry outlets such as Fierce Pharma have documented the company’s prior disclosures. Local trackers say the combined job losses have landed hard on the state’s life-sciences cluster.
What Catalent Says And Regulatory Context
Catalent has previously told reporters that its layoffs stemmed from an “unexpected shift in demand from a large customer,” and the company has said it provides severance and outplacement support to affected workers, according to Pharma Manufacturing. At the same time, industry reporting has highlighted recent inspection observations at Maryland gene-therapy facilities, a development that trade coverage and inspection databases indicate coincided with some staffing moves. Public inspection records in ProPublica’s Rx Inspector and related reporting have noted agency observations that analysts say add operational pressure for manufacturers working at commercial scale. None of that makes it easier for sites trying to juggle compliance, costs, and a now-shakier demand picture.
Local Impact
Catalent’s Maryland operations rank among the state’s largest for gene-therapy manufacturing, so every new cut lands with extra weight. Earlier WARN notices drew attention from elected leaders and workforce advocates, CBS Baltimore reported. Regional trackers and local outlets have been tallying layoffs across biotech and CDMO employers through 2025 and into 2026, and community figures say they are pressing for clear communication on severance, benefits, and possible redeployment for affected staff. For many employees, the latest round comes after months of watching the demand picture wobble while waiting to see which sites would bear the brunt.
What Comes Next
The Maryland Department of Labor maintains a public WARN log and runs Rapid Response services that can help laid-off workers with job searches, retraining options, and benefits referrals. Those filings are how many of the earlier Catalent cuts became public in the first place. According to the state site, the speed and scope of assistance depend on how employers coordinate and how fast local workforce teams can mobilize. Catalent has not immediately shared further public details on how the newest 96 job cuts are structured beyond what business outlets have already reported, leaving many in the region watching the WARN log and trade press for the next update.
